The association between oral disease and type of antiretroviral therapy among perinatally HIV-infected youth

Objectives: This study explores the association between combination antiretroviral therapy (cART) and oral health outcomes (dental and periodontal) among perinatally HIV-infected (PHIV) youth. Methods: We conducted a cross-sectional study of oral health among PHIV youth participating in the Oral Health substudy of the Pediatric HIV/AIDS Cohort Study (PHACS). Dentists at research sites were trained/calibrated on how to perform a standardized oral mucosal, dental and periodontal examination. They assessed the decayed-missing-filled-surfaces and teeth index (DMFS/T). The number of decayed surfaces and teeth and the number of teeth with gingival bleeding on probing for each participant were derived from the examination. Data for analysis included lifetime measurements of CD4+ cell count and viral load, sociodemographic information and current/past history of ART. Results: Among 209 PHIV youth, 95% were on ART at the time of enrolment. Among 143 PHIV youth on the same cART for at least 1 year, we found that the mean decayed teeth score of those receiving cART containing an integrase inhibitor was 86% higher than that of those on cART without an integrase inhibitor after adjusting for age, lifetime proportion of unsuppressed viral load and CD4+ cell count nadir. Initiating protease inhibitors before age 6 years was associated with a significantly lower DMFT score than participants who initiated at age 6 years and older. Conclusion: Our study revealed that PHIV youth who received cART containing an integrase inhibitor had a significantly higher number of untreated active caries than those on cART without an integrase inhibitor. This may warrant closer dental surveillance of those receiving an integrase inhibitor.

[1]  Paige L. Williams,et al.  Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus–Infected Youth , 2017, JAMA pediatrics.

[2]  Anna-Barbara Moscicki,et al.  The Burden of Oral Disease among Perinatally HIV-Infected and HIV-Exposed Uninfected Youth , 2016, PloS one.

[3]  O. Gbolahan,et al.  Oral and dental lesions in HIV infected Nigerian children , 2015, The Pan African medical journal.

[4]  C. Shiboski,et al.  Oral lesions among HIV‐infected children on antiretroviral treatment in West Africa , 2014, Tropical medicine & international health : TM & IH.

[5]  Anna-Barbara Moscicki,et al.  Prevalence of and risk factors for substance use among perinatally human immunodeficiency virus-infected and perinatally exposed but uninfected youth. , 2014, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[6]  P. Eke,et al.  Update of the case definitions for population-based surveillance of periodontitis. , 2012, Journal of periodontology.

[7]  D. Hazuda,et al.  HIV-1 antiretroviral drug therapy. , 2012, Cold Spring Harbor perspectives in medicine.

[8]  L. Muwazi,et al.  Oral Manifestations in HIV/AIDS-Infected Children , 2011, European journal of dentistry.

[9]  L. Mofenson,et al.  Antiretroviral Treatment of US Children With Perinatally Acquired HIV Infection: Temporal Changes in Therapy Between 1991 and 2009 and Predictors of Immunologic and Virologic Outcomes , 2011, Journal of acquired immune deficiency syndromes.

[10]  S. Solomon,et al.  Orofacial and systemic manifestations in 212 paediatric HIV patients from Chennai, South India. , 2010, International journal of paediatric dentistry.

[11]  J. Chmiel,et al.  AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study , 2010, AIDS.

[12]  Paige L. Williams,et al.  Declines in Mortality Rates and Changes in Causes of Death in HIV-1-Infected Children During the HAART Era , 2010, Journal of acquired immune deficiency syndromes.

[13]  J. Beck,et al.  Rethinking periodontal inflammation. , 2008, Journal of periodontology.

[14]  John D Seeger,et al.  Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  S. Solomon,et al.  Oral lesions among persons with HIV disease with and without highly active antiretroviral therapy in southern India. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[16]  J. Greenspan,et al.  Oral Lesions of HIV Disease and HAART in Industrialized Countries , 2006, Advances in dental research.

[17]  P. Economopoulou,et al.  Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. , 2004, Oral diseases.

[18]  S. Gange,et al.  Incidence of Oral Lesions in HIV-1-infected Women: Reduction with HAART , 2004, Journal of dental research.

[19]  V. Ramírez-Amador,et al.  The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico , 2003, Medicine.

[20]  A. Tappuni,et al.  The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. , 2001, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[21]  L. Gaitán-Cepeda,et al.  Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? , 2000, AIDS patient care and STDs.

[22]  F. Bergmann,et al.  Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. , 2000, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[23]  W. Powderly,et al.  Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis , 2000, AIDS.

[24]  L. Patton,et al.  Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. , 2000, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[25]  M. Navazesh,et al.  Methods for Collecting Saliva , 1993, Annals of the New York Academy of Sciences.

[26]  C. Christensen,et al.  Clinical Criteria for the Diagnosis of Salivary Gland Hypofunction , 1992, Journal of dental research.

[27]  H. Löe,et al.  PERIODONTAL DISEASE IN PREGNANCY. II. CORRELATION BETWEEN ORAL HYGIENE AND PERIODONTAL CONDTION. , 1964, Acta odontologica Scandinavica.

[28]  Victor Badner,et al.  Prevalence of periodontal diseases in a multicenter cohort of perinatally HIV‐infected and HIV‐exposed and uninfected youth , 2017, Journal of clinical periodontology.

[29]  S. Naidoo,et al.  Oro-facial manifestations in paediatric HIV: a comparative study of institutionalized and hospital outpatients. , 2004, Oral diseases.

[30]  V. Badner,et al.  Prevalence of oral lesions and percent CD4+ T-lymphocytes in HIV-infected children on antiretroviral therapy. , 2003, AIDS patient care and STDs.

[31]  C. Palmer,et al.  Studies on Dental Caries. I. Dental Status and Dental Needs of Elementary School Children. , 1938 .